title: [Validity of cardiovascular prescriptions to the guidelines in the elderly according to the STOPP and START method].
abstract: Cardiovascular diseases are the first cause of death in elderly patients. So it seems important to estimate the adequacy of the medical prescriptions to the guidelines in this population and for these diseases. A retrospective analysis was performed in nine hospitals on 736 patients aged 65 years old and over hospitalized in the acute care geriatric unit. Cardiovascular prescribing were analyzed for each patient according to STOPP and START. The population (n=736) has a mean age of 86.7 years and belongs in 45.0% of the cases to the group of dependence GIR3-4. According to STOPP, two inappropriate prescriptions are noticed: calcium channel blockers with chronic constipation concerning 9% of the included population and aspirin at dose > 150 mg/day representing 8.4% of this population. According to START, angiotensin converting enzyme inhibitor are under-prescribed in elderly patients with heart failure (140 patients = 19.0% of the population) and following acute myocardial infarction (116 patients = 15.8%). Anticoagulation in patients with atrial fibrillation is also under-prescribed: 82 patients are concerned (11.0% of the population). The prescription of ACE inhibitor is influenced by renal insufficency in patients with heart failure. The anticoagulation in atrial fibrillation is age and dependence-related. This analysis demonstrates an inadequacy between the clinical practice and guidelines for two major cardiovascular diseases: the heart failure and the atrial fibrillation. The importance of the inadequacy was suspected of opportunities for improvement, in particular in the presence of their risk factors: very elderly patients, loss of autonomy and renal insufficiency.
authors.affiliation: Service de médecine gériatrique, Hôpital Decker, Centre hospitalier Bretagne Atlantique, Vannes, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Coupet
authors.forename: Delphine
authors.initials: D
authors.lastname: Renvoize
authors.forename: Camille
authors.initials: C
authors.lastname: Rousseau
authors.forename: Marc
authors.initials: M
authors.lastname: Fresil
authors.forename: Philippe
authors.initials: P
authors.lastname: Lozachmeur
authors.forename: Dominique
authors.initials: D
authors.lastname: Somme
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000453:epidemiology; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D003248:Constipation / Q000139:chemically induced / Q000453:epidemiology; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005602:France; D019983:Guideline Adherence; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D057970:Inappropriate Prescribing; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000453:epidemiology; D012189:Retrospective Studies
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents
keywords: STOPP-START; cardiovascular diseases; drug prescriptions; elderly